Epizyme (EPZM) Given a $12.00 Price Target at Morgan Stanley

Share on StockTwits

Morgan Stanley set a $12.00 target price on Epizyme (NASDAQ:EPZM) in a research note released on Friday, MarketBeat.com reports. The firm currently has a hold rating on the biopharmaceutical company’s stock.

EPZM has been the topic of several other reports. Zacks Investment Research upgraded Epizyme from a hold rating to a buy rating and set a $15.00 target price on the stock in a research note on Tuesday, July 24th. Cann reiterated a buy rating and issued a $27.00 target price on shares of Epizyme in a research note on Thursday, August 2nd. Leerink Swann downgraded Epizyme from an outperform rating to a market perform rating and set a $24.00 target price on the stock. in a research note on Tuesday, July 3rd. BidaskClub upgraded Epizyme from a sell rating to a hold rating in a research note on Wednesday, July 11th. Finally, HC Wainwright reiterated a buy rating and issued a $25.00 target price on shares of Epizyme in a research note on Monday, May 21st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $21.73.

NASDAQ:EPZM traded up $0.15 during mid-day trading on Friday, reaching $10.15. 407,225 shares of the stock were exchanged, compared to its average volume of 247,597. The company has a market capitalization of $695.03 million, a PE ratio of -4.66 and a beta of 1.81. Epizyme has a 1 year low of $8.61 and a 1 year high of $21.40.

Epizyme (NASDAQ:EPZM) last released its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.11. The firm had revenue of $12.00 million for the quarter, compared to analysts’ expectations of $0.54 million. The company’s quarterly revenue was up 20.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.48) EPS. equities research analysts predict that Epizyme will post -2.09 EPS for the current fiscal year.

Several hedge funds have recently made changes to their positions in EPZM. Point72 Asset Management L.P. boosted its stake in shares of Epizyme by 525.0% in the first quarter. Point72 Asset Management L.P. now owns 750,000 shares of the biopharmaceutical company’s stock valued at $13,313,000 after buying an additional 630,000 shares in the last quarter. Voya Investment Management LLC boosted its stake in shares of Epizyme by 95.0% in the second quarter. Voya Investment Management LLC now owns 1,182,983 shares of the biopharmaceutical company’s stock valued at $16,029,000 after buying an additional 576,436 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Epizyme by 10.4% in the second quarter. BlackRock Inc. now owns 4,303,720 shares of the biopharmaceutical company’s stock valued at $58,315,000 after buying an additional 406,541 shares in the last quarter. Citadel Advisors LLC boosted its stake in shares of Epizyme by 39.3% in the second quarter. Citadel Advisors LLC now owns 810,119 shares of the biopharmaceutical company’s stock valued at $10,977,000 after buying an additional 228,405 shares in the last quarter. Finally, Opaleye Management Inc. boosted its stake in shares of Epizyme by 292.9% in the second quarter. Opaleye Management Inc. now owns 275,000 shares of the biopharmaceutical company’s stock valued at $3,726,000 after buying an additional 205,000 shares in the last quarter. Institutional investors own 85.07% of the company’s stock.

About Epizyme

Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.

Featured Story: Growth Stocks

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply